Guardant Health, Inc., a leading precision oncology company, announced that Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal...
New research in the June 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that when alectinib—a safe and effective small molecule kinase inhibitor used to...
As a result of recent research revealing that a significant number of colorectal cancer patients with actionable variants are missed under previous genetic testing...
The National Comprehensive Cancer Network Oncology Research Program (ORP) announced a collaboration with Pfizer Global Medical Grants (Pfizer) that awards new grants to advance...
